SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
SAN DIEGO, Oct. 24, 2017 -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report third quarter 2017 financial results on Tuesday, November 7, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Conference Call Information
| Date: | Tuesday, November 7, 2017 |
| Time: | 4:30 p.m. ET |
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) |
| Confirmation code: | 3889648 |
| Live webcast: | Retrophin.com in the "Events & Presentations" section of the "Investors" page |
A replay of the call will be available from 7:30 p.m. ET, November 7, 2017 to 7:30 p.m. ET, November 14, 2017. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 3889648.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare diseases. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research exploring additional rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam® and Thiola®.
Contact:
Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications
646-564-3680
[email protected]
